Ifosfamide, Paclitaxel, and Thiotepa Combination

The combination of ifosfamide, paclitaxel, and thiotepa is a high-dose chemotherapy regimen studied primarily for metastatic breast cancer and germ cell tumors. It is typically administered with peripheral blood progenitor cell (PBPC) and filgrastim support to manage significant bone marrow suppression. Recommended doses established in phase I studies are: Ifosfamide: 10 g/m², Thiotepa: 350 mg/m², and Paclitaxel: 175 mg/m². This regimen was administered in cycles every 28 days in clinical trials, with progressive dose-escalation in successive cohorts. Dose-limiting toxicities include renal tubular acidosis, encephalopathy, mucositis, and enterocolitis, with one reported treatment-related hemorrhagic death in a phase I study. While efficacy data for this exact combination are limited in the provided search results, related regimens like TIP (paclitaxel, ifosfamide, and cisplatin) have shown promising results in relapsed or refractory germ cell tumors, achieving high complete response rates and long-term remissions.